10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch

10x Genomics, Inc. (NASDAQ:TXG) is one of the best digital health stocks to buy now.

On October 29, 2025, 10x Genomics announced the launch of its next-generation Chromium Flex assay, designed to help researchers dramatically scale up single-cell experiments. The upgraded system introduces a 96-well plate format that supports up to 384 samples and processes as many as 100 million cells per week. It integrates with automated workflows, allowing scientists to multiplex large numbers of samples while minimizing reagent waste.

The new assay builds on the company’s existing Flex chemistry and is aimed at two key areas: high cell-number applications like CRISPR screens, and high sample-number applications such as FFPE-based translational research. 10x says this release will allow labs to achieve throughput levels previously only possible with bulk methods, while retaining single-cell resolution. CTO Michael Schnall-Levin called it a “transformational step forward” for foundational and translational research.

Chromium Flex is now globally available and targets academic, biotech, and pharma labs that require automated, high-throughput solutions for precision cell profiling.

10x Genomics, Inc. (NASDAQ:TXG) is a life sciences tools company that develops platforms for single-cell and spatial biology. Its technology enables high-resolution molecular analysis across oncology, immunology, neuroscience, and other research domains.

While we acknowledge the potential of TXG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.